Phase 2 MetaCURE trial of apalutamide-based multimodal therapy plus prostatectomy in high-risk localised (A) or low-volume metastatic (B) prostate cancer: pathological complete response or minimal residual disease in 12% (A) and 15% (B).
RCT
McHugh et al. Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial